OBJECTIVES: @entity62 syndrome is a @entity16 after organ transplantation caused predominantly by the @entity2359 effects of immunosuppressive agents on cerebral white matter. We determined the incidence and features of @entity62 in recipients after living-donor liver transplantations. MATERIALS AND METHODS: We retrospectively investigated 205 @entity1 who had a living-donor liver transplantation performed at our institution between August 1998 and October 2008. RESULTS: @entity62 syndrome developed in 7 of 205 @entity1 (3.9%) and in 4.7% of the 150 @entity1 treated with @entity1140 -based immunosuppression after their living-donor liver transplantation. The underlying diseases were @entity7160 in 3 cases, viral @entity82 in 2, @entity2876 in 1, and @entity2360 in 1. Time to clinical onset after @entity1140 medication was 15.6 days (range, 6-30 days). The neurologic symptoms included @entity10 , @entity911 , @entity2045 , @entity410 , and @entity227 . The mean serum trough level of @entity1140 at clinical onset was not very high (11.7 ng/mL [range, 6.0-14.2 ng/mL]). T2-weighted magnetic resonance imaging in all cases showed diffuse high signal in the white matter of the frontal, parieto-occipital, and temporal lobes. Treatment with antihypertensives, anticonvulsants, and withdrawal of @entity1140 resulted in amelioration of symptoms and magnetic resonance imaging abnormalities. Six @entity1 showed complete recovery, while the seventh had @entity2003 and @entity73 caused by @entity519 during a @entity410 . CONCLUSIONS: @entity1140 @entity2359 can occur despite low trough levels; it depends on variations in pharmacokinetics, such as absorption and maximum concentration level. Early diagnosis and treatment of @entity62 should contribute to complete remission.

XXXX syndrome after living-donor liver transplantation.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity410 :: ('MESH:D012640', 'Disease') :: ['seizures', 'convulsion'] @entity82 :: ('MESH:D005355', 'Disease') :: ['cirrhosis'] @entity227 :: ('MESH:D014786', 'Disease') :: ['visual disturbances'] @entity2003 :: ('MESH:D009127', 'Disease') :: ['residual rigidity'] @entity2045 :: ('MESH:D009207', 'Disease') :: ['myoclonus'] @entity73 :: ('MESH:D003072', 'Disease') :: ['cognitive impairment'] @entity16 :: ('MESH:D009422', 'Disease') :: ['neurologic complication'] @entity10 :: ('MESH:D006261', 'Disease') :: ['headache'] @entity519 :: ('MESH:D000860', 'Disease') :: ['hypoxia'] @entity2360 :: ('MESH:D006527', 'Disease') :: ['Wilson disease'] @entity911 :: ('MESH:D003221', 'Disease') :: ['confusion'] @entity1140 :: ('MESH:D016559', 'Chemical') :: ['Tacrolimus', 'tacrolimus'] @entity2876 :: ('MESH:D001656', 'Disease') :: ['biliary atresia'] @entity62 :: ('MESH:D056784', 'Disease') :: ['Leukoencephalopathy', 'leukoencephalopathy syndrome'] @entity7160 :: ('MESH:D008104', 'Disease') :: ['alcoholic cirrhosis'] @entity2359 :: ('MESH:D020258', 'Disease') :: ['neurotoxic', 'neurotoxicity']
@entity62 :: (MESH:D056784,Disease) :: ['Leukoencephalopathy']
